Skip to main content
. Author manuscript; available in PMC: 2013 Mar 18.
Published in final edited form as: Mol Cancer Ther. 2009 Jan;8(1):178–184. doi: 10.1158/1535-7163.MCT-08-0643

Figure 6.

Figure 6

Expression of CD44, LYVE-1, and CD34 by prostate tumors. Sections from PC3 tumors were excised from mice following gp120-IIIB treatment, stained for CD44, LYVE-1, or CD34 expression, and counterstained with hematoxylin. Representative sections from three separate experiments (×20 magnification), with groups containing five mice each.